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Summary At histopathological diagnosis of non-Hodgkin's lymphoma (NHL) the mean number of mitoses
in 10 high power fields (x40) was determined in thin sections (2ym) and designated 'mitotic index' (MI). In
38 patients the thymidine labelling index (LI) of the lymphoma cells was also determined. There was a close
correlation between MIs and LIs (r=0.81, P<0.001) indicating that MI reflects the proliferative activity in
NHL. Among 101 patients with NHL classified according to the Kiel nomenclature MIs were generally lower
in lymphomas of low grade malignant type than in the high grade malignant lymphomas. The variation of
MIs within morphological subgroups was especially pronounced in high grade lymphomas. Only 18 of 49
patients (37%) with MI.2 have survived for 2 years in contrast to 37 of 52 patients (77%) with MI<2
(P=0.001). For patients with histologically low grade lymphomas and MI.2.0 the median survival was 23
months and for those with MI<2.0 58 months (P=0.09). Patients with high grade lymphomas and MI>2.0
had a median survival of 15 months compared to 57 months for those with MI <2.0 (P=0.04). In a
multivariate analysis of 50 patients with centroblastic-centrocytic (CB-CC) or centroblastic (CB) lymphomas
the importance of different prognostic factors was analysed. Among the variables age, MI, growth pattern
(follicular vs. diffuse), cell type (CB-CC vs. CB), clinical stage (I vs. II-IV), initial chemotherapy (active vs. less
active) only age and MI gave significant prognostic information.
It is concluded that the assessment of mitoses in NHL gives prognostic information in addition to
histopathologic classification. The method is simple and the proliferative activity and histopathological
diagnosis can be ascertained routinely on the same occasion.
In non-Hodgkin's lymphoma (NHL) histopathologic classi-
fication is of importance for evaluation of prognosis and
choice of therapy. Among the various systems for classifi-
cation used, the Kiel classification (Lennert, 1978) has
proven valuable for these purposes (Cavallin-Stahl et al.,
1981; Glimelius et al., 1983; Brittinger et al., 1984).
According to the results from several studies the deter-
mination of the proliferative activity of lymphoma cells gives
considerable prognostic information in addition to
morphologic classification. In these studies uptake of
thymidine (Brandt et al., 1981; Costa et al., 1981; Kval0y et
al., 1985) or the determination of cells in Sphase by flow
cytometry (Roos et al., 1985) have been used to assess the
proliferative activity of the lymphoma tissue.
In the present work the number of mitoses has been
assessed in biopsy material from patients with NHL
classified according to the Kiel classification. The prognostic
importance of the method has been evaluated by analysis of
survival of the patients.
Materials and methods
Patients
The material comprises 107 patients with NHL diagnosed in
1976-1983. In 6 patients the biopsy material was not con-
sidered optimal for an assessment of the number of mitoses.
Thus 101 patients were included in the study. There were 54
men and 47 women aged 31-89 years (median 66 years).
Twenty-three patients presented with a single involved site-
11 with a nodal site and 12 with an extranodal lesion. The
remaining 78 patients were in stage II-IV. All patients were
followed for a minimum of two years or until death. Follow-
up was performed in our hospital or in close collaboration
with other hospitals in our region.
Histopathologic examination
Five gm sections were cut from the biopsy specimens and
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stained with H & E and according to Gordon's and Sweet's
method to demonstrate reticulin. From these sections the
gross architecture of the lymphoma was evaluated, i.e.
whether it was follicular, follicular and diffuse or diffuse.
Thin, 2ym sections were prepared and stained with H & E,
May-Griinwald-Giemsa (MGG) and PAS according to
McManus to evaluate the cellular composition of the
lymphoma. In some cases imprint preparations from fresh
lymphoma tissue were available and the classification was
then based on a combined analysis of sections and imprints.
Determination ofmitotic activity
In the thin, 2pm sections, stained with H & E the number of
mitoses was recorded in 10 high power fields (x 40). The
total number of mitotic figures was divided by ten and the
quotient was designated mitotic index (MI). In order to
evaluate the reliability of MI, the number of mitoses was
recorded on two occasions in 10 patients. On the second
determination the pathologist was unaware of the outcome
of the first assessment of MI. All determinations of MI were
performed by one pathologist (M.A).
Determination oflabelling index
Material from the lymphomas was obtained through
aspiration. Cell suspensions were incubated with tritiated
thymidine and the percentage labelled lymphoid cells (LI)
was determined in autoradiography preparations as
described previously (Brandt et al., 1981).
Staging procedures
Clinical staging was performed according to the Ann Arbor
classification (Carbone et al., 1971). The staging procedures
have been described previously (Brandt et al., 1981) and did
not include staging laparotomy.
Treatment
Histopathology, stage, age and performance status were the
main factors used to determine treatment. Generally patients
with localized disease, stage I-II, were treated with radio-
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therapy and patients with disseminated disease, stage III-IV,
received chemotherapy.
Patients with high grade malignant lymphomas were
generally treated with CHOP (cyclophosphamide, doxo-
rubicin, vincristine and prednisone), CHOP+methotrexate
or MEV (methotrexate, cyclophosphamide and vincristine).
Patients with low grade malignant lymphomas were
generally treated with either CVP (cyclophosphamide,
vincristine and prednisone) or prednimustine, a chlorambucil
ester of prednisolone. In those patients treated with CVP
and/or prednimustine, who did not respond to treatment, the
treatment was changed to CHOP or MEV.
Since the patients were diagnosed within a fairly long
period of time, treatment has not been uniform. In the
analysis of the impact of MI compared to other prognostic
factors (see below) the initial therapeutic regimens were
therefore dichotomized into intense (CHOP, CHOP+metho-
trexate and MEV) and less intense (CVP and prednimustine).
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Survival
Survival was recorded from the date of diagnosis until death
or date of last follow up.
The Kaplan-Meier method was used for the univariate
estimation of survival time; differences in survival times were
tested by generalized Wilcoxon statistics. For the follicle
center cell lymphomas (FCC) of centroblastic-centrocytic
(CB-CC) and centroblastic (CB) type a multivariate analysis
was performed using Cox's proportional hazard analysis
(Cox, 1972). By means of mathematical modelling, the
impact of MI was evaluated in relation to known prognostic
factors: age at diagnosis, growth pattern, lymphoma type,
stage and treatment. The relative risk of dying was exempli-
fied for the continuous variables age and MI. Each of the
variables growth pattern, lymphoma type, stage and treat-
ment was dichotomized into two categories and the relative
risk was calculated for each factor. Two-sided P-values are
given for the significant factors.
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Figure 1 Correlation between mitotic indices (MI) and labelling
indices (LI) in 38 patients with non-Hodgkin's lymphoma.
Results
Repeated assays ofMI
The MIs recorded on two occasions in 10 patients are shown
in Table I. In each patient the difference between the two
MIs was small, on average 0.7.
Table I Results of repeated determinations of MI
in 10 patients
Mitotic indices
Assessment no. 1 2 Difference
Patient no. 1 0.5 0.3 0.2
2 0.8 1.2 0.4
3 0.8 1.2 0.4
4 1.2 1.2 0.0
5 2.5 2.9 0.4
6 3.6 2.2 1.4
7 7.2 8.1 0.9
8 8.0 8.6 0.6
9 8.3 9.6 1.3
10 10.1 8.6 1.5
Relation between MI and LI
In 38 patients the MIs and Lls were determined (Figure 1).
There was a significant correlation between the number of
mitoses recorded and the number of cells in S phase as
determined by LI (r=0.81, P<0.001).
MI and morphology
The MIs in various morphologic subgroups of NHL are
shown in Figure 2. In low grade malignant lymphomas MIs
were generally low and there was only a small variation of
MI within the various morphologic groups. The centrocytic
(CC) lymphomas constituted an exception with a marked
heterogeneity. There were no obvious differences in MIs
when comparing follicular versus diffuse growth pattern in
CB-CC lymphomas.
In the high grade malignant lymphomas there was a
considerable variation in MIs suggesting a great variation in
proliferative activity.
MI and survival
In NHL a large proportion of patients surviving the first 2
years after diagnosis will be long term survivors (Leonard et
al., 1983). Forty-six patients have died within two years. The
median MI for these patients was 2.8. For the 55 patients
who have survived for more than two years the median MI
was 1.3 (Figure 3). In order to further evaluate the
prognostic impact of MI, the patient material was divided
into two groups of about the same size: 49 patients with
MI.2.0 and 52 patients with MI<2.0. In the former group
only 18 patients (37%) have survived for 2 years. Among
patients with MI<2.0 37 patients (71%) have survived for
more than 2 years (X2 = 12.05, P=0.001).
MI, morphology and survival
Survival was significantly longer (P=0.003) in the low grade
malignant lymphomas (median 57 months) compared to the
high grade malignant lymphomas (median 15 months).
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Figure 2 Mitotic indices (MI) in different morphologic subgroups of non-Hz
classification.
LC =lymphocytic, IC=immunocytic, CB-CC=centroblastic-centrocytic, CC =centro
LB =lymphoblastic, H =true histiocytic, unclass =unclassifiable.
(0) polymorphic immunocytoma, (A) follicular or follicular+diffuse, (O) large cell.
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Figure 3 Mitotic index (MI) in relation to two years survival in
patients with NHL. (0) dead intercurrently.
For patients with low grade malignant lymphomas and
MI<2 the median survival was 58 months and for those
with MI_2 median survival was 23 months (Figure 4). The
difference does not reach statistical significance (P=0.09).
For the patients with high grade malignant lymphomas and
MI<2 the median survival was 57 months compared to 15
months for those with MI .2 (P=0.04, Figure 5).
A separate analysis of the prognostic impact of MI was
performed in the patients with follicle center cell lymphomas
(FCC) of the CB-CC and centroblastic (CB) subtypes. This
group comprised 50 patients after exclusion of 3 patients
who died from intercurrent disease. Age and MI were used
as continuous variables. Growth pattern was categorized as
either follicular or diffuse. Lymphomas with follicular and
diffuse pattern were referred to the follicular group. Clinical
stage was separated into two groups stage I or stage II-IV.
The lymphomas were dichotomized into CB-CC or CB.
Initial treatment was divided into two groups - intense
chemotherapy (CHOP, CHOP-M and MEV) or less intense
(CVP and Prednimustine). The results are shown in Table II.
Among the selected variables only age and MI gave
significant prognostic information.
Discussion
The present study was undertaken to investigate if the
proliferative activity in NHL, estimated as the number of
mitoses in histologic sections, may have prognostic impli-
cations. If the proliferative activity, measured as a mitotic
count, is of prognostic value it was considered advantageous
that the histopathologic diagnosis and MI can be determined
on the same occasion.
Assessment of the number of mitoses calls for well fixed
tissue without necrosis or crush artefacts. In our material
these criteria were not fulfilled in 5% of the biopsies,
although a diagnosis of NHL was possible to obtain. Even if
optimal preparations are available the proposed method has
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Figure 4 Actuarial survival in 59 patients with low grade
malignant lymphoma according to MI.
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Figure 5 Actuarial survival in 42 patients
malignant lymphoma according to MI.
with high grade
some pitfalls; the number of lymphoma cells may vary in
different parts of a section. This is apparently not a serious
drawback since the results of repeated determinations of MI
were fairly constant. Another objection is that MI is not
strictly related to the number of cells in the visual fields. In
the large cell lymphomas, which constitute the high grade
malignant group, the number of cells examined in 10 visual
fields will naturally be lower than in the low grade malignant
lymphomas. This might cause a relative underestimation of
the MI in high grade malignant lymphomas.
Table II Prognostic factors in follicle center cell lymphomas.
Cox's proportional hazard analysis. The relative risk is
exemplified for each factor. P values are given for the
significant factors
Factor Relative risk P value
Age at diagnosis 0.05
a difference of +20 years 2.1
Mitotic index 0.03
2 vs. 1 1.6
3vs. 1 2.1
4vs. 1 2.7
6 vs. 1 4.4
Growth pattern NS
diffuse vs. follicular 1.4
Lymphoma type NS
CB vs. CB-CC 1.2
Stage NS
II-IV vs. I 1.4
Treatment NS
intense vs. less intense 1.0
In spite of these shortcomings the results indicate that this
simple method might have clinical implications. The close
correlation between MIs and LIs suggests that the deter-
mination of MI gives information on the proliferative
activity of the lymphoma cells. Moreover, there was an
association between MIs and the histopathological grading
of malignancy, i.e. low grade malignant lymphomas had
generally lower MIs than high grade ones.
Low MIs with only small differences among patients in
the same subgroup were recorded in lymphocytic lymphomas
and immunocytomas. There was a relatively wide range of
variation of MIs in the CB-CC group and among the CC
lymphomas there was considerable heterogeneity. The
highest MI were recorded in lymphomas of high grade
malignant type, and there was a striking variation in MI
within the various subgroups. These findings are in good
agreement with reports on the proliferative activity in NHL
using other methods (Brandt et al., 1981, Barlogie et al.,
1983, Costa et al., 1981; Christensson, 1983; Hansen et al.,
1981; Roos et al., 1985; Gerdes et al., 1984).
The MI is obviously related to survival. About half of the
patient material had a MI>2.0. Only 37% of these patients
have survived for more than two years whereas 71% of the
patients with MI<2.0 are alive more than two years after
diagnosis. Low grade malignant lymphomas with MI>2.0
were associated with a shorter median survival time
compared to low grade malignant lymphomas with MI<2.0.
In high grade malignant lymphomas survival was signifi-
cantly shorter for the patients with a MI.2.0 than for those
with a lower MI. Although the number of patients in each
subgroup of low grade and high grade lymphomas was
rather small, the results suggest that MI offers prognostic
information in addition to the Kiel histopathological classi-
fication. It remains to be determined whether the assessment
of MI is also valuable using other schemes of classification,
e.g., the Working Formulation.
According to the Kiel nomenclature the follicle center cell
(FCC) lymphomas constitute a large part of the NHL and
the CB-CC (low grade) and CB (high grade) types are most
common (Glimelius & Sundstrom, 1982; Brittinger et al.,
1984). The distinction between these two types of
lymphomas may sometimes be uncertain. Moreover, it is
sometimes difficult to ascertain whether the growth pattern
is follicular, follicular and diffuse or entirely diffuse. Such
distinctions might also be of prognostic importance. It was
therefore considered worthwhile to further explore the
prognostic value of MI in CB-CC and CB lymphomas. In a
multivariate analysis age, growth pattern, lymphoma type,
clinical stage, and initial treatment were prognostic factors
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tested for in comparison to MI. Age and MI turned out to
be significant predictive factors and the others did not add
further information. Thus the proliferative activity of CB-CC
and CB lymphomas appears to be an independent prognostic
variable.
With current treatment programs a low proliferative
activity of lymphoma cells is compatible with long term
survival (Brandt et al., 1981; Costa et al., 1981; Gronowitz et
al., 1983; Kval0y et al., 1985; Roos et al., 1985). For patients
with rapidly proliferating lymphomas, new therapeutic
regimens are needed. A prompt and simple evaluation of the
mitotic activity in histological preparations may help to
select these patients for future therapeutic trials.
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